# Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

> **NCT01902173** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced Melanoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Malignant Solid Neoplasm
- Unresectable Melanoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dabrafenib Mesylate
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Trametinib Dimethyl Sulfoxide
- **DRUG:** Uprosertib

## Key facts

- **NCT ID:** NCT01902173
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-08
- **Primary completion:** 2018-05-16
- **Final completion:** 2023-12-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902173, "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01902173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*